Clinical Trial

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is the first clinical study of Neoadjuvant and Adjuvant treatment of head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with PD-1 inhibitors, which explores the new combination therapies urgently needed in clinical practice and lays a foundation for subsequent studies, with important scientific research significance and clinical value.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-10-17; most recent amendment 2025-07-28.
Status change: Recruiting → Active, Not Recruiting 2025-07-28
Trial Details
NCT Number NCT05586100
Lead Sponsor Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Conditions Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
Enrollment 52 participants
Start Date 2022-10-13
Primary Completion 2025-04-28 (estimated)
Study Completion 2026-04-28 (estimated)
Updated on ClinicalTrials.gov 2025-07-31